(aminomethyl)phosphonic acid CAS:1066-51-9

(aminomethyl)phosphonic acid

Chemical Name:   (aminomethyl)phosphonic acid
CAS.NO:1066-51-9
Synonyms:
(Aminomethyl)phosphonic acid
aminomethylphosphonic acid

Molecular Formula:CH6NO3P
Molecular Weight:111.03700

Physical and Chemical Properties:
Density: 1.635 g / cm3
Boiling point: 358ºC at 760 mmHg
Melting point: 300 ° C
Flash point: 170.3ºC
Refractive index: 1.505

Specification:
Appearance: white to off-white powder
Purity:≥98%
Moisture Content: ≤0.3%
Impurity: ≤0.3%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Telavancin hydrochloride CAS:560130-42-9



We are professional (aminomethyl)phosphonic acid manufacturer and aminomethylphosphonic acid supplier in China, We offer quality (Aminomethyl)phosphonic acid you can fully trust, also we have India factory and producer of (Aminomethyl)phosphonic acid,Pls send inquiry of aminomethylphosphonic acid CAS:1066-51-9 to info@nbinno.com if you have any interests, thank you!


Related News: In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.4-Benzoylpyridine Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.446-32-2 Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.1-Naphthylamine Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”